Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CMMB
CMMB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CMMB News
Market Update: Tilray Drives After-Hours Gains as Biotech Stocks Soar
Dec 15 2025
NASDAQ.COM
Top Strong Buy Stocks for October 23: MQ, GES, and Others
Oct 23 2025
NASDAQ.COM
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Oct 23 2025
NASDAQ.COM
ESPR Seeks Diversification Through Rare Liver Disease Candidate, Shares Rise
Oct 17 2025
NASDAQ.COM
CDTX Shares Rise Following FDA's Breakthrough Therapy Designation for CD388 in Influenza
Oct 10 2025
NASDAQ.COM
Oppenheimer Reiterates Outperform Rating for Chemomab Therapeutics and Increases Price Target to $25
Aug 27 2025
Benzinga
Stock Splits Scheduled for This Week (August 25 to August 29) – Keep Your Investments Active
Aug 24 2025
TipRanks
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25
Jun 30 2025
Newsfilter
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
Jun 11 2025
Newsfilter
KURA Stock Rises More Than 15% This Past Week: Here's Why
Jun 06 2025
NASDAQ.COM
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
May 05 2025
Newsfilter
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases
Apr 28 2025
Newsfilter
Chemomab Announces New Medical and Clinical Appointments
Apr 15 2025
Newsfilter
Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease
Mar 27 2025
Benzinga
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis
Mar 06 2025
Newsfilter
Chemomab Therapeutics (CMMB) Gets a Buy from Oppenheimer
Mar 04 2025
Business Insider
Show More News
